Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages

  Ferretti, Gianluigi ^a   Fabi, Alessandra ^a   Felici, Alessandra ^a   Papaldo, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; BREAST TUMOR; METABOLISM; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 77954716653     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.2525     Document Type: Letter

References (5)

1. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
2. Papaldo P, Fabi A, Ferretti G, et al: A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: Changing the natural history of HER2-positive disease. Ann Oncol 17:630-636, 2006
3. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
4. Gasparini G, Gion M, Mariani L, et al: Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101:355-365, 2007 (Pubitemid 46169890)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)